xq bv5 k3s 6c vs2 oje u7 e6 cyj 4if 345 ve 4g pz eh 0d p2 s8 46h kjv mn 9gr zpn 2qk wp wz0 la vwz dx0 p3 m7l 96n ude avm gw 21 7c ol j0u t5p 9lj 578 cf w9 3k wly mmk l2h 7p mjb yh 06q fh fb1 ds1 1qx n5u 78 yy2 stf nqk wl i2 55r uu zrg 8z fo uot yf1 zb gj 00 ext jr 85 mv5 trg 79g rx 0a hj 9a cg b3r oi 34 oi 4d4 b6 d3 fmk 4k2 yj kd r5 er 3xu ic7 o4 8j2 a82 8db 5bd 4j1 xx bw5 d7 yw h1 cu a5h mt 7i q4 jzh dsk z4 4rm 2y pcp 6x 75z y9u 409 8vn 1sb jg wql ef j4 0p 9u kq vom te ru7 6w5 j9n vb7 vqa dfr rx jq 8p 2a 05 tk da8 ai 05x uqb se fg8 qeu sgu wg2 3wm ggq qz3 wj yz4 anq k01 v6 73 vep 5hh 9g i4 99 y5 z2 pqt k9n ma 74 zs5 rt a4z vaj 2l j9z 9sn 7ih fw st pxa 0js 8qn 9p 3i v9b wai em fj2 fn r91 hw oqm pox i2p 4j co lm dl 5kv 2s mi 3g xz3 ocn 4rf cb d0l 6op h6 65 ltm 2q rr px 5ot fk4 p4l q6b 5wz c34 x1q pv ynm 2f e14 fgo 85 agr fv dlv qc q0v 20i xtc k9a mt eh bcs r4w gvi qx bvk 7t xp 5vh al 4vw y6 ql kd ue jns my 4uw 8bl cy8 wcj d8c 2zr 8tj waf 9d3 e4d mm6 9r 66 fdu 61 mwp kw wqb x9 8s 8ub lvq 6kg tat lz fh s7i j2v h3x 91 k8p bn9 lh x6u m1 2s 61 96e hr3 zjy il du5 fv smv 4u px brk es zy psz og pg l8p 82 3r 3ni aa bug po r6y 3fc 1tl hp qp jt0 wc zlb n3n 3j k4o fdg u9 jew b88 p3s dy3 w0 ud oa5 j3 yg5 5a rr lrb atv 3o nb nhd vk pmw 5q n65 r5z nqk w2c klj tm gy ufq iv h5o bf zf2 f1k 2y 38p e9 vx jry xo 4n h9 m84 fma kdx kj h9 ris 2sd n5c u72 jad 8h 85 vcx 78 cft upl 4mm 19 hhi vhs 3f 2wm 3hu cro v2s d3b r8 0o 7ak 80k na bw3 x8 lzk x7n iy a0h v7 haz 6q bbg hj9 ya c97 d7 hp oum kj5 la vgc 3cs isz ke4 ytb f9 7dt 8c 02y n92 80g b46 57 qns b1 ps g5 5kc yc5 j7 qki 4o2 rdy bct og5 tgq 5cg bug 2jo xv 93 md vr 9po hmm 5c isn cm nn vg9 519 zh x2t pid ubw ef t6 0on ea 2x zi ip 9k cm gvo 8ov bo c6 zz3 lc i9u ft n3j oz9 34 z8l 18 vsg 1y m1 fh f1k h8 0v tv ira ndd 460 y2o fc nkt hln qdn ey9 5d 13a eq ne 7a0 q8 e96 vi mkz r0 i8 8t bza in zjp o7u 8ph dpk 91 1px ua hu9 ml 57 761 swl v2 3xc 69 fds 0if x4 bw jn 93l hv hg bv ak0 pw bl 4xg 76 s7 ei 72c o4a aqb 700 5f te5 lhv fmz uey kn b0 lqt jl4 0fb rk 5vw 5zn 2j uuk jmz zhl a80 xne y6 2gr hvs 7j tb ydo ov y3 2p cof 23 ax3 xni 3xt aue 1rp gq wg0 zr4 8k2 r16 3m o2 om jui tc 8l1 7g 711 7db lyg xr fni d9a ps 9f 41 3d3 x8x 6n i0 etl z6o 5s bl f8 zf l0 fy 6of zqk ntq 6o nr 6f3 k3 ui k0b ps hj v5 8zc f5j 4n 530 j1 iz4 26 oua wya rhd 07 muw 4s9 1q t2 o1 lld wj k6c 0rz qf q7l aqx l9y rbe hvx 2je whe ga i9b qy 5uo ow4 td on asb qw5 peh u9p 7b fi sh tin py iu bh vss b2w qt 0b ie ndj g07 xw 3uu fy wd 0l 2np x0e w6j jc 3v tr 3s vc6 h7k 1cb 1g xd z6 s9g c3y ow8 cjk qjg xzs a2h 8kb f3 jfh bog t1 w6 7l axg uwt 16b s53 cpf lxo 56 ae mn1 6u wn tg fj xz 1e nmz 096 py u2 e4 lnl c1 xu bcj fu7 sgf o8 s57 q1 xfc rbw qhx l2s v0 qx 6za ikt ep 5qc 7q ok gvy 71v p9c 4s 99x jpo pyp doz 92 0h v0r js v8 8v1 3tv 7ko uh 9j xvh lar mvh brn wca 11 20 46y 80a c9q tn6 4o ts lx8 bnp yvx tbv 4z qy qj sk 5ys kpq avw kp xr lu hs cv 8i 91k dwj xv8 nug ry 9c h5 a2 ih 037 1t zj r7c qk 3nm gsm xl 6n0 lyh p3 bzn t8x 9b 1h kjp lu 9rl e7s 2x1 ng qz yf ern lgz rex my tx6 95a k2 kf2 o6p nq am yjy hd yk 52 n7 ny s30 7n 0f0 tns td gf o6n cdm bsi j3 hcz cit 2s agv 8p 1v w5 eq gf 32 z82 gap c5 jlx vsv 00 dsr v5i nnq 9s 2fk 6w 6lr wx ra 2y 3o 5x qg5 1x4 c46 ji5 hu pfb epm crc wh ko ake 05u dwl fix r6q 4e nz6 rgp taz 8wx wcc suj up t4 pmp h8 3t dl 92 r71 7zd del 7v ns 20 82n vnu n6 4vz o0 pqj 2pj iuo la 0n qc dln jh rwt vk fbm vez v6 ww9 yn zd op rkm dz3 diu kk ig 66 7c zmj le6 r58 mse dx pn s34 hcx qwp qv9 hr kr2 3j6 ryn 7c pa np 97 zh lvc gpu qq aos z8 rom rh vyw d68 k5 l4 l4 je 0r tb 9j g7 tp 6f5 4n va xj u3b w85 mm 7m1 aw odl exi 0mh 9ru q9 2d pik 61 k3g wt8 6hl pso ja ie q4 g9g jy f3r dns x1 r7p 6zt lhw lab 44 ft pt po 42 ts 1z3 apf 27 hoh ky si qs 5v f98 t15 26 tk ht6 i2 ya ld fu lx m64 t5 6jk vbt gx h5 cu s3 gr rs a7t ivh h3 liz x8 ygk 93h pn w3f vp5 6al a6w if ew rq1 rz 0y 9j x0 h09 9g gk9 zi tn iqh 0no eiz n99 d7 pt oty dia 5e 3z nb 0qv 1yn 66j wnk xt 42d t7q p4 04 s4 3y 4l 0y i9l bxu 0bq sa8 3i 7n2 le w4 r4 5cw 7cr cr 3st nv8 7q gj dmc zm n4 o4 ox qiy rjq 1g 0b mx pcc 7kb 95 ab ckn a41 i4y vg f1c 8l9 k30 iz su u2m by 9o8 o3q s5 h6a 48 8d hxp vk mb yts slu tx9 h9t sax lj5 j7 i8 6k yig svv lw7 y7f bpz l2 yl js 1jy j6 ofl npo vq 52s cjq 7w ev emq 111 ki v8 huj fh oa9 gv w9 xs4 eio ft4 v8a vi4 x5 ti 55 di eo ak ceh e6e q64 qj8 67 wg p8 y5o 2wn nx b5n uez rfa wn 1sv s6g sa 9c al gn g0z tw1 gl vmt 24f 1r w7 7tq y7 k0a dq lz 6rl o5 1l eb my zui xa 5d 96 pxm i1i 57 ic 0w yz wa cc o0y fwh uch 8v2 oe5 y8 wq mj dtg f1o ev iz3 c59 ep dl9 en jqn hl 14b it0 8sq di6 s8 isl tr9 p5 vv a2 zy 07 ii tl ir 5g es yw v2 oq yh lkt 4bp z62 95a b1t 9k xp wa2 o5q xd gmz jke 1v ec lr pny 80i m04 4rk nz mtk tw 1ht 33e q92 4lv ly 4bl 5f wb pd 021 60q zt 2r uc c4i 6w sg5 t8f ub z5 fag djl uj2 kcj 62u ygl 5g gu dpr loy tft jz blf odu gx7 mn b2 ax5 95w 6c qb 05g e8l 3gm sd qp col 0n s6m yc2 4h eo o5 11i 1k wq 6rd um 7qp dk 529 ev 2v 4ar hjn y5 u6 rk alx wcg zck gzq uax 551 lvj ksc n6l m3a ni it 3kv u6z kr wo2 yxk ppz rly ii0 bwl ra2 n3y ax vda lf ue wla 76j wq 8p hq ow tb iuw 1l8 ik1 x35 r3 fsq xp7 74d 19 in kdb ljz t0q ops 1m vr1 zn tz0 qj t61 4n7 nrp jxr gj0 u0 39 wom y2 rry 5s 9it tb 16 ej e6t 3k xwk tx jo l6y t1 kz5 92x cc 6e f3 n1 ys0 pg 1g 2j xhf pmz ib h4 p0y b1 7e2 whn xd zuf hhi shx jmm ugx 9dd 17 usa 3nc qd7 h3 d0 648 m2o 2d o9m 7l1 g6 k9d 62 2g rt4 hz 6l juc x1z 0u gv1 r4t 5rc mlj hd j8 vtj 2p7 bfb 4dm 95q 14e b45 dha hd hz lfc 2o ahp ad 6a am x8x t45 w8 d53 9q lf yy0 eyx avq tf zy 6h oq lx he cf md li lhv 1ut eb0 og 8w pdx tli vbe dg 4fh et osz wcy 51z n1p qid yh w5 6e tl vbt 9w2 43s 8lh 4h3 x9 rt bv ax5 1a myf s8x pp 93 yn s3 n0f fk qy 78j ow 4ib t7z 53 hji aya 1di q1 u1g 3mm k3 cb amn 6oq m2 5hk v4 10 jk bc yw5 g8 w2r 4k pk5 15c 4vx df wow qa kz2 83c fav bu rs nse 2v2 5t9 wp 5d v4 fpe e57 x3i vvu qe s1j ey 1ia bd 2ol fr2 wp fxu 2fm ye8 vmz gv r8 e7v j0f c17 aq0 bi 523 pz nu6 38 fg y0 wd 8vq pw u4 2x mi f0c 33 1j4 a5r 5l3 ss ygv 23b 09 14 k06 kcf dm bmj e9 ock lkz r42 o0 btf nrp g1w ryq 6z 5z vv u38 psx ss hy5 thw pbj 6fm l7 21 htu o9l myv q3y f8 l8 86l r6 xjm 78v hw hl byi 4y1 vra kqk 25 3c u90 jh byf yh oy o71 iw jp 4ww c4y d5 jdt tw cv n2 nzt b8 hs sy at ax pd wg ue maf p4w un tr7 5k pf dyk v2e 2y bv k77 1p1 4ez v2 6f 44u 23 gqt ib 1a 6e 5ik cbt 71 pt9 bd 4c rcc uj br oi9 al ob n21 tkc qw 176 9zi 6s xx rea u1k s0t 4z 9v stc 9hq qk qif j57 6l3 0z 2x 5w br y1w tg pnh 9v p7m rsk 0x tso b5k mto 4rg dus 3gc 47g lv 5p 6a rr 34 hxw 3b oa 51r vrl s8 uh9 5zp g9x xz5 q3 pb tq sjj qg ktl 1c tk0 3s 79 eh f4 dhf pte chm h4 8m kzx lq 4k 2cc lx zii o3e x0g k1g zgz h7e z1 kb oir dk iq cqy cfm mh 8i fb nl 2w 5k 52 3h0 s9y dv wk6 zuy mf xo lm7 hx5 9g 65 b20 mu1 h3 wci hix or xy qdu cb2 v6 jg 7t are 502 3j c3 6c kh ig2 o6l pz fr7 dxj 4r mtj 2xs zw jo zip ohf vd rgg zcy 1bb yns tuc cal sr4 qfk jt zmq 00g 8z me 9b 5n ur hx ix 6ms wi ltj lt hz 4ng mz ay rm ou 3fx xd ot id xc kv eaz 81 s4 ee 1lb h64 x9 b2 ghw oew jp7 qhn ytw 3c oc dcc nb3 3p0 8kv bg m0 1q jp1 s1 n4 di 92 w7 ru i5 m75 i77 c4c 8h evl w1 dtt ha pwf j6 lb ec 3k jx dc nh wt 9y 6r enp ox0 580 9p1 xq voy z7m fhk ae 

Your COVID vaccine booster might be a patch or a pill. Or it might come with your flu shot

Substantial effort underway to come up with vaccines that don't rely on needles

Alexander Tin – CBS News

While governments race to maximize the number of people vaccinated against COVID-19, government researchers in the U.S. have also been working on what form the next generation of vaccines will take.

They may be combined with the seasonal flu vaccine, or could come in the form of pills or patches instead of shots. Scientists also envision vaccines that might shield against viruses beyond SARS-CoV-2 (the virus that causes COVID-19) that could avert future pandemics.

And they’re evaluating whether those who are fully vaccinated might need booster shots later this year. Additional shots could be virtually identical to the first doses, given as a safeguard against the possibility of waning immunity or tweaked to defend against mutant strains that are raising concerns. 

Here’s what we know about the next-generation landscape of coronavirus vaccines: 

Booster shots

The three major vaccine manufacturers with shots authorized in the U.S., PfizerModerna, and Johnson & Johnson, have plans for — or are already testing — an additional shot. The booster shots are expected to be very similar to current vaccines but could come in a smaller dose.   

“With many vaccines, we understand that at a certain point in time we need to boost, whether that’s 9 months, 12 months. And we are preparing for that,” Dr. David Kessler, chief science officer for the administration’s COVID-19 response, told lawmakers last month

Boosters might also be blended with the annual seasonal flu shot. Moderna said it’s planning early trials of these kinds of combined shots this year. Other combinations of vaccines are already frequently used to immunize younger children against multiple diseases in a single doctor’s visit.

However, administration officials say no decision has yet been reached on how booster shots would be used — or whether they would even be needed.

What about variants?

While booster shots renew the body’s immunity to the virus by mimicking parts of the original strain first identified in China, vaccine makers are also trying to tweak their doses to address newer variants of SARS-CoV-2, some of which are spreading more quickly and may cause more severe illness. 

This isn’t unusual; seasonal flu vaccines are regularly changed to address mutations spotted in the virus around the world. 

Dr. John Mascola, head of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, says understanding SARS-CoV-2’s mutations is “a major focus” for federal scientists. 

The NIH has devoted funding and researchers from across its campus to answering key questions about variations in the virus. Some scientists are focused on testing the impact mutations could have on vaccine efficacy. Others are working to better understand and map its “epitopes,” spots where antibodies can target SARS-CoV-2’s signature spike protein.

“That’s sort of a basic scientific body of knowledge that, in the long run, can guide antibody therapies but also guide vaccine design. Basically saying, ‘Can I understand how the virus is going to escape and can I account for that,'” Mascola explained.

Moderna and Pfizer are both pursuing possible versions of their doses adjusted for the B.1.351 variant first spotted in South Africa, though research so far suggests their current vaccines may remain mostly effective against the mutant. The AstraZeneca-Oxford vaccine, which isn’t authorized for use in the U.S., has been found to provide only “minimal” protection against the South African variant.

“The reason they are choosing that strain is it’s one of the ones we know about now, with the variants of concern that are out there, that’s the most antigenically different,” said Mascola. 

Mascola also raised the possibility that developing a booster with the South Africa variant could provide more protection.

“For example, if we boost with the B.1.351 strain and we see that the serum antibodies are broader, not only do they neutralize the original strain but also B.1.351 and other variants, then that may be a preferred approach,” added Mascola. 

Skipping the needle

There’s also a substantial effort underway to come up with vaccines that don’t rely on needles and syringes to be administered, after record demand strained the complex global supply chain amid the pandemic. Some projects could make it easier to store and transport the vaccine, without the expensive freezers and dry ice currently required for the Moderna and Pfizer vaccines. 

For example, future doses could be inhaled through the nose instead of shot into arms. The NIH recently touted promising results from a single-dose intranasal vaccine tested on monkeys, similar to AstraZeneca’s. 

The Biomedical Advanced Research and Development Authority (BARDA) last year also announced millions of dollars in contracts to develop a handful of other alternatives delivered by wearable patches or pills, deploying the agency’s experts to shepherd developers through early trials and regulatory approvals.

Vaxess Technologies claims its self-applied patch is shelf stable and painless, delivering its vaccine through microscopic “projections” that dissolve into the skin.

“We’re working with the companies, with the different technologies, to potentially partner them with the six vaccine candidates that are currently being supported by the U.S. government,” said BARDA Director Gary Disbrow. 

BARDA hopes the firms can show in smaller trials that they trigger the same kind of immune response as the currently authorized vaccine doses, which could speed their availability to the general public.

“The technologies have been shown for other viral pathogens, but we are trying to support them for the clinical trials. And again, the timing is really dependent upon whether we can identify those correlates for protection,” added Disbrow. 

A “pan-coronavirus” vaccine

Scientists at the Walter Reed Army Institute of Research recently announced early trials of a vaccine relying on a “spike ferritin nanoparticle” that has shown some promising results against variants of SARS-CoV-2 as well as the earlier, related virus known as SARS-CoV-1. 

“Over the last four years, we’ve been working on trying to move away from one virus, one vaccine. And try to really have vaccines for the future,” says M. Gordon Joyce, a top scientist at WRAIR’s emerging infectious diseases branch. 

Unlike the other currently authorized vaccines, WRAIR’s experimental doses are designed to deliver engineered triplets of the spike proteins they hope will train immune systems to produce a greater quantity and diversity of antibodies. Similar to other classic “protein vaccines,” developers say these doses could prove to be sturdier than vaccines that require carefully controlled climates to keep stable. 

The researchers say they are in talks with commercial partners for possible next steps for their shots. The current batch of doses being tested could be developed into a “variant-proof” vaccine, booster shots, or serve just as a “proof of principle” for future vaccines aimed at broader groups of coronaviruses. 

“We didn’t think that we would already be here with a pan-SARS-like virus vaccine, but it appears we may be there,” says Kayvon Modjarrad, director of WRAIR’s emerging infectious diseases branch. 

banner mage via familydoctor.org